Log In
BCIQ
Print this Print this
 

NOV110302

  Manage Alerts
Collapse Summary General Information
Company National OncoVenture
DescriptionFLT3 inhibitor
Molecular Target FMS-like tyrosine kinase 3 (FLT3) (CD135)
Mechanism of ActionFMS-like tyrosine kinase 3 (FLT3) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationAcute myelogenous leukemia (AML)
Indication DetailsTreat acute myelogenous leukemia (AML)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today